TEVA has also sold $3.375B of preferred stock that automatically converts into common stock on 12/15/18. The conversion price is $62.50-75.00, based on the market price at the time of conversion.
The $6.58B net proceeds from the two offerings will be used to pay a portion of the consideration for AGN’s generic-drug business.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.